Searched for
IPCA LABORATORIES NEWS
Ahead of Market: 10 things that will decide stock market action on WednesdayDomestic equities closed marginally lower due to weakness in financial and consumer shares, despite gains in IT stocks. Analysts suggest th...- Reduce Ipca Labs, target price Rs 1,250: Prabhudas LilladherIpca Labs (IPCA) Q1 EBITDA of Rs 3.9 bn was in line with our estimate. Management guidance of 9% revenue growth (excluding Unichem) was bel...
- Reduce Ipca Laboratories, target price Rs 1150: Prabhudas LilladherIpca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 31697.80 Crore) operating in Pharmac...
- Stock Radar: This pharma stock is likely to top Rs 1000 levels in 1-2 months; time to buy?The stock rose from Rs 731 on 20 June to Rs 913 recorded on 20 September, which translates into an upside of 24% in 3 months. It hit a fres...
- Ipca to acquire 33.4% stake in Unichem Labs for Rs 1,034 crore"The Board approved entering into a definitive Share Purchase Agreement (SPA) for the acquisition of 2,35,01,440 fully paid-up equity share...
- Buy Ipca Laboratories, target price Rs 1105: JM FinancialIpca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 21837.59 Crore) operating in Pharmac...
- Accumulate Ipca Laboratories, target price Rs 1000: Prabhudas LilladherFor the quarter ended June 30, 2022, the company has reported a consolidated total income of Rs 1607.85 crore, up 23.34 per cent from last ...
- Buy Ipca Laboratories, target price Rs 930: EdelweissIpca Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue, Export Incentives, Sale of services ...
- Buy Ipca Laboratories, target price Rs 1110: JM FinancialIpca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 23416.90 Crore) operating in Pharmac...
- Hold Ipca Laboratories, target price Rs 2240: Emkay GlobalIpca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 26838.10 Crore) operating in Pharmac...
- Ipca Labs Q2 results: Net profit declines 6% to Rs 250 croreThe board has "approved subdivision of every 1 equity share of the nominal/face value of Rs 2/ each into 2 equity shares of the nominal/fac...
- Buy Ipca Laboratories, target price Rs 2400: Motilal OswalIpca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 27807.25 Crore) operating in Pharmac...
- Buy Ipca Laboratories, target price Rs 2400: Motilal OswalIpca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 26410.61 Crore) operating in Pharmac...
- Buy Ipca Laboratories, target price Rs 2420: Motilal OswalIpca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 25078.03 Crore) operating in Pharmac...
- Buy Ipca Laboratories, target price Rs 2680: Motilal OswalIpca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 28586.53 Crore) operating in Pharmac...
- IndiaNivesh maintains ‘accumulate’ rating on IPCA Labs, target price Rs 1,550IndiaNivesh projects a 17% sales CAGR and 29% PAT CAGR over FY19–22, wherein the EBITDA margin is expected to expand by 200bps to 22% by FY...
- Ipca Labs Q1 profit at Rs 65 croreTotal income stood at Rs 867.56 crore for the quarter under review.
- Ipca Laboratories tanks 11% as Geneva-based fund not to source malaria drugShares of Ipca Laboratories ended at their lowest level in 36 months on news that Switzerland-based The Global Fund will not source malaria...
- Should investors buy Ipca Labs after US import alert?It can take anywhere between 15-20 months for the company to resolve the issue. The USFDA had issued Form 483 to Ratlam API in mid 2014.
- IPCA Lab reports 10.5 per cent loss, wipes out Rs 995 crore from its market valuationShares of IPCA Laboratories ended with sharp losses of 10.5 per cent, wiping-out Rs 995 crore from its market valuation today, amid reports...
Load More
